Hospital purchasing data and Special Authority approvals for azacitidine
20 July 2020
Dear [name and contact details withheld]
REQUEST FOR INFORMATION
Thank you for your email of 22 June 2020 requesting information about units of azacitidine purchased by DHBs and Special Authority approvals for azacitidine from 2017 to 2020.
Your request has been considered pursuant to the Official Information Act 1982 (OIA).
The information you have requested is listed in the table below.
Table 1: Purchased units of Azacitidine in the DHB hospitals for the relevant period
|
|
Year ending 30 June 2017 |
Year ending 30 June 2018 |
Year ended 30 June 2019 |
Year ended 30 June 2020 |
|---|---|---|---|---|
|
Azacitidine 100mg vial (Vidaza) |
46.99 |
154.85 |
-112.42 |
0 |
|
Azacitidine 100mg vial (Azacitidine Dr Reddy's) |
0 |
0 |
267.54 |
242.52 |
Table 2: Special Authority approvals for initial and renewal applications (SA1467) for Azacitidine for the relevant period
|
|
Year ending 30 June 2017 |
Year ending 30 June 2018 |
Year ended 30 June 2019 |
Year ended 30 June 2020 |
|---|---|---|---|---|
|
Initial approvals (Total) |
93 |
120 |
131 |
103 |
|
Initial approvals for intermediate-2 or high risk myelodysplastic syndrome |
53 |
71 |
79 |
58 |
|
Initial approvals for chronic myelomonocytic leukaemia |
14 |
12 |
17 |
16 |
|
Initial Approvals for acute myeloid leukaemia |
25 |
34 |
24 |
21 |
|
Renewal approvals |
|
|
|
|
|
Total renewal approvals |
37 |
50 |
50 |
37 |
Please note that data relating to purchased units of azacytidine is only available up to and including March 2020, therefore the year ended 30 June 2020 is not a complete data set.
Special approval numbers represent distinct patients. The special approval numbers do not necessarily tally, as some initial approvals did not include information about the condition.
The negative number for Vidaza stock in 2018/19 represents DHBs selling on its stock as the product was delisted.
We trust that this information answers your queries. We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.
Yours sincerely
Rachel Read
Manager, Policy and Government Services